Abstract：
The concept of oligometastatic disease was first introduced in the late 1990s to describe an situation more or less midway between locally advanced tumours and multifocal metastatic cancer. Four concepts are currently used: synchronous oligometastatic disease, metachronous oligometastatic disease (or oligo-recurrence), oligo-persistence and oligo-progression. Some phase II studies, randomised or not, have validated this concept in non-small cell lung cancer (NSCLC) and suggest the interest of adding local ablative therapy to systemic treatment. That said, numerous questions remain, and the impact of this therapeutic approach in the framework of immunotherapies and targeted therapies has yet to be assessed. Which of these new treatments offer hope of significantly improved long-term survival in stage IV NSCLC? This article appraises current knowledge and therapeutic regarding oligometastatic NSCLC.
摘要：
寡转移疾病的概念最早是在1990年代后期引入的，目的是描述局部晚期肿瘤和多灶性转移性癌症之间或多或少的情况。目前使用四个概念：同步寡转移疾病，异时寡转移疾病(或寡复发)，寡聚持久性和寡聚进展。一些第二阶段的研究，随机与否，在非小细胞肺癌（NSCLC）中验证了这一概念，并建议在全身治疗中增加局部消融疗法。那就是说,仍然存在许多问题，这种治疗方法在免疫疗法和靶向疗法框架下的影响尚待评估.这些新疗法中哪一种提供了显著改善IV期NSCLC长期生存率的希望？本文评估了有关寡转移NSCLC的最新知识和治疗方法。
